Hypersensitivity reactions to biological drugs

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 4, 2014, Pages 212-225

  Corominas, Mercé ^a   Gastaminza, G ^b   Lobera, T ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL SAN PEDRO   (Spain)

Author keywords

Biological drugs; Diagnosis; Hypersensitivity; Monoclonal antibodies; Skin tests

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DRUG HYPERSENSITIVITY; HUMANS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906860396     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Walsh G. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. Eur J Pharm Sci. 2002;15:135-138
2. Pichler WJ. Adverse side effects to biological agents. Allergy. 2006;61:912-20
3. Biobadaser. Registro Español de acontecimientos adversos de terapia biológica en enfermedades reumáticas. Informe Enero 2013. www.biobadaser.ser.es
4. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. Safety-regulatory actions for biologicals approved in the United States and The European Union. JAMA. 2008;300:1887-96
5. Maggi E, Vultaggio A, Matucci A. Acute infusions reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63
6. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanism to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11:262-8
7. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24
8. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012;8:43-52
9. Guzzo JA, Nichols TC. Possible anaphylactic reaction to abciximab. Catheter Cardiovasc Interv. 1999;48:71-3
10. Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy. 2003;58:688-9
11. Moneret-Vautrin DA, Morisset M, Vignaud JM, Kanny G. T cell mediated allergy to abciximab. Allergy. 2002:57:269-70
12. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA. Safe administration of a humanized murine antibody, after anaphylaxis to a chimeric murine antibody. Transplantation. 2002;74:1697-700
13. Baudouin V, Crusiaux A, Haddad E, Schandene L Goldman M, Loirat C, Abramowicz D. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the anti-interleukin 2 receptor monoclonal antibody basiliximab. Transplantation. 2003;76:459-63
14. Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with basiliximab. Transplant Proc. 2003;35:579
15. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. High incidence of Cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25:3644-8
16. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Josen J, Mauro D, Slebob RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. Cetuximabinduced anaphylaxis and IgE specific for galactosa-alfa-1-3- galactose. N Engl J Med. 2008;358:1109-17
17. Daguet A, Watier H. 2nd Charles Richet et Jules Héricourt Workshop. Therapeutic antibodies and anaphylaxis; May 31- June 1, 2011; Tours, France. www.landesbioscience.com
18. Commins SP, James HR, Kelly ES, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E, Cooper PJ, Platts-Mills TAE. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-a-1,3galactose. J Allergy Clin Immunol. 2011;127:1286-93
19. Mariotte D, DuPont B, Gervais R, Galasis MP, Laroche D, Tranchant A, Comby E, Bouhier-Leporrier K, Reimund JM, Le Mauff B. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. Mabs. 2011;3:396-401
20. Saif MW, Syrigos KI, Hotchkiss S, Shanley J, Grasso J, Ferencz TM, Syrigos K, Shah MM. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patient with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2009;65:107-12
21. Nielsen DL, Pfeiffer P, Jensen BV. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab. Ann Oncol. 2009;20:798
22. Jerath, MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, Platts-Mills TAE, Tarrant TK. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol. 2009;123:160-1
23. Jankowitz R, Joyce J, Jacobs SA. Anaphylaxis after administration of Ibritumomab Tiuxetan for follicular non- Hodgkin lymphoma. Clin Nucl Med. 2008;33:94-6
24. Muñoz-Cano R, Carnes J, Sanchez-Lopez J, Saiz A, Bartra J, Lopez-Matas MA, Picado C, Valero A. Biological agents: New drugs, old problems. J Allergy Clin Immunol. 2010;126:394-5
25. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391-403
26. Hellwing K, Schimrigk S, Fisher M, Haghikia A, Müller T, Chan A, Gold R. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008;65:656-8
27. Camacho-Halili M, George R, Gottesman M, Davis-Lorton M. An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Mult Scler. 2011;17:250-3
28. Cox L, Platts-Mills TA, Finegold I, Lawrence B, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Omalizumab-Associated Anaphylaxis Joint Task Force report on omalizumab associated anaphylaxis. J Allergy CIin Immunol. 2007;120:1373-7
29. Corren J, Casle TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exper Allergy. 2009;39:788-97
30. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28:313-9
31. Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts- Mills T, Schwartz L. American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128:210-2
32. Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol. 2010;105:494-5
33. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Reumatol. 2007;13:94-5
34. Tonelli AR, Lottenberg R, Allan R, Sriram PS. Rituximab-induced hypersensitivity pneumonitis. Respiration. 2009;78:225-9
35. Brennan PJ, Rodriguez Bouza T, Hsu I, Sloane DE, Castells MC. Hypersensitivity reactions to monoclonal antibodies: 105 desensitizations in 23 patients, from evaluation to treatment J Allergy Clin Immunol. 2009;124:1259-66
36. Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, Alterini R, Rigacci L, Rogmanani S, Maggi E. Drug-specific Th2 cells and IgE antiboidies in a patients with anaphylaxis to Rituximab. Int Arch Allergy Immunol. 2012;159:321-6
37. Piva E, Chieco-Bianchi, Krajcar V, Aversa S, Plebani M. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test. Am J Hematol. 2012;87:E130-1
38. Castells M, Tennant NM, Sloane DE, Hsu FI, Barret NA, Hong DI. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy CIin Immunol. 2008;128:574-80
39. Abadoglu O, Epozturk K, Atayik E, Kaptanoglu E. Successful and rapid desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option. J Investig Allergol Clin Immunol. 2011;21:319-21
40. Vila AT, Puig L, Fernández-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. British J Dermatol. 2005;153:417-23
41. Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, Colburn N. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacoth. 2009;43:967-72
42. Puig-Sanz L, Saez E, Lozano MJ, Bordas X, Carrascosa JM, Gallardo F, Luelmo J, Sanchez-Regana M, Alsina M, Garcia- Patos V. Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr. 2009;100:103-12
43. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol. 2000;95:2395-6
44. Gori T, Munzel T. A case of coronary hypersensitivity (Kounis) syndrome associated with mid-ventricular ballooning pattern, intracoronary thrombosis and troponin elevation. Int J Cardiol. 2011;149:377-8
45. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008; 159:527-36
46. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8
47. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657-61
48. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138:1258-9
49. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol. 2004;16:627-30
50. Manso L, Polo B, Fernandez-Nieto M, Sastre LB, del Pozo V, Sastre J. Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (adalimumab). J Investig Allergol Clin Immunol. 2010;20:537-8
51. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96:128-30
52. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009;102:1133-40
53. George SJ, Anderson HL, Hsu S. Adalimumab-induced urticaria. Dermatol Online J. 2006;12:4
54. Mallo S, Santos-Juanes J. Adalimumab-induced urticaria. Actas Dermosifiliogr. 2007;98:511-2
55. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedemalike skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007;26:787-8
56. Paltiel M, Gober LM, Deng A, Mikdashi S, Aleexeve I Sami SS. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008;144:1190-4
57. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011;106:547-8
58. Benucci, M Manfredi, P Demoly, P Campi. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy. 2008;63:138-9
59. Puig L, Bordas X, Carrascosa JM, Dauden E, Ferrandiz C, Hernanz JM, Lopez-Estebaranz JL, Moreno JC, Sanchez-Carazo JL, Vanaclocha F, Vazquez Veiga H. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2009;100:277-86
60. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-26
61. Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nunez- Cornejo C, Castera MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J. 2009;102:304-5
62. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26:71S-7S
63. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol. 2007;34:577-82
64. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142-6
65. Guillot B, Blazquez L, Bessis D, Dereure O, Ghilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology. 2004;208:49-54
66. Beckman DB, Mathisen TL, Harris KE, Boser MB, Grammer LC. Hypersensitivity to IFN-alpha. Allergy. 2001;56:806-7
67. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 1991;85:220
68. Kendirli T, Kismet E, Demirkaya E, Aydin HI, Kesik V, Köseoglu V. Death possibly associated with interferon use in a patient with chronic hepatitis. Acta Paediatr. 2005;94:984-5
69. Kilic M, Dogan Y, Taskin E, Sen Y, Kalpaklioglu AF. Desensitization protocol administered successfully with interferon-alpha 2a in a child with chronic hepatitis B infection. J Invest Allergol Clin Immunol. 2010;20:447-8
70. Manjón-Haces JA, Vázquez-López F, Gómez-Díez S, Hidalgo- García A, Pérez-Álvarez R, Soler-Sánchez T, Pérez-Oliva N. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol. 2001;81:223
71. Sookoian S, Neglia V, Castaño G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol. 1999;135:1000-1
72. Helbig D, Simon JC, Treudler R. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b. Acta Derm Venereol. 2010;90:308-9
73. Taghavi SA, Eshraghian A. Successful interferon desensitization in a patient with chronic hepatitis C infection. World J Gastroenterol. 2009;15:4196-8
74. Walther EU, Hohfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622-7
75. Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology. 1999;52:425
76. Mazzeo L, Ricciardi L, Fazio MC, Fogliani O, Fedele R, Ferlazzo E, Isola S. Severe urticaria due to recombinant interferon beta- 1a. Br J Dermatol. 2003;148:172
77. Brown DL, Login IS, Borish L, Powers PL. An urticarial IgEmediated reaction to interferon beta-1b. Neurology. 2001;56: 1416-7
78. Fusun Kalpaklioglu A, Baccioglu Kavut A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case report. Int Arch Allergy Immunol. 2009;149:178-80
79. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153:1088-90
80. Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, Careddu GF, Montesu MA, Tocco A, Lissia A, Solinas A. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol. 2004;84:120-3
81. Veldt BJ, Schalm SW, Janssen HL. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. J Clin Gastroenterol. 2007;41:432
82. Barut S, Yuksek J, Sezer E, Gunal O, Koseoglu D. Morbiliform drug eruption due to pegylated a-interferon can show complete regression after switching to non-pegylated interferon. J Dermatol. 2011;38:479-81
83. Tang DM, Ward L. Rash form hepatitis C treatment. Cleve Clin J Med. 2011;78:472-4
84. Sato M, Sueki H, Iijima M. Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Clin Exp Dermatol. 2009;34:e814-7
85. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928-35
86. Loppow D, Huland E, Heinzer H, Grönke L, Magnussen H, Holz O, Jorres RA. Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. Eur J Med Res. 2007;12:556-62
87. Banerji A, Weller PF, Sheikh J. Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich's Syndrome). Immunol Allergy Clin North Am. 2006; 26:769-81
88. Abraham D, McGrath KG. Hypersensititivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. Allergy Asthma Proc. 2003;24:291-4
89. Assmann K, Nasham D, Grabbe S, Luger TA, Meetze D. Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates. Hautarzt. 2002;53:554-7
90. Junghans RP, Manning W, Safar M, Quist W. Biventricular cardiac thrombosis during interleukin-2 infusion. N Engl J Med. 2001;344:859-60
91. Sasaki O, Yokoyama A, Uemura S, Inoue N, Hiwada K. Drug eruption caused by recombinant human G-CSF. Intern Med. 1994;33:641-3
92. Martin M, Pienkowski T, Mackey J, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Proveneher L, Walde D, Rodríguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawasky M, Riva A, Vogel C. Adjuvant docetaxel for node-positive breast cancer. New England J Med. 2005;352:2302-13
93. Bux J, Cassens U, Dielschneider T, Duchscherer M, Edel E, Eichler H, Haas C, Moog R, Peschke H, Peters C, Ryzenkov I, Schlenke P, Ulrich H, Wiesneth M. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and patients towards granulocyte transfusions: results of a multicenter study. Vox Sang. 2003;85:322-5
94. Batel-Copel L, Mommeja-Marin H, Oudard S, Chauvenet L, Pujade-Lauraine E, Coupier J, Bernadou A. Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection. Eur J Cancer. 1995;31A:2428
95. Jayesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony stimulating factor and acute anaphylaxis. N Eng J Med. 1991;325:587
96. Martín Muñoz R, Gómez-Bellver MJ, Navarro Pulido AM, Orta Cuevas JC. Probable hypersensitivity reaction to filgrastim. Am J Health Syst Pharm. 1996;53:1607
97. Viallard AM, Lavenue A, Balme B, Pincemaille B, Raudrant D, Thomas L. Lichenoid cutaneous drug reaction at injection sites of granulocyte colony-stimulating factor (Filgrastim). Dermatology. 1999;198:301-3
98. Chichmanian RM, Heudier P, Taillan B, Fuzibet JG. No cross hypersensitivity between molgrastim and filgrastime: apropos of a case. Therapie. 1995;50:478-9
99. Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors. Cancer Chemother Pharmacol. 1997;40:353-7
100. Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough L, DiPersio JF. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukaemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25:1197-201
101. Tulpule S, Shaw BE, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. Bone Marrow. 2009;44:129-30
102. White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol. 2006;31:206 -7
103. Cernelc P, Andoljsek D, Mlakar U, Pretnar J, Modic M, Zupan IP, Zver S. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathesis. Pflugers Arch. 2000;440:R81-2
104. Engler RJ, Weiss RB. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction. Ann Allergy Asthma Immunol. 1996;76: 531-4
105. Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Caspasso E, Caraglia M, Del Prete S. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/ epidoxorubicin/cyclophosphamide. Eur J Cancer Care (Engl). 2010;19:200-4
106. Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S. Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption. Br J Dermatol. 2009;161:717-9
107. Hanna GG, Edgar D, Clarke JE. A case of prolonged type 1 hypersensitivity reaction to pegfilgrastim. Clin Oncol. 2008;20:315-6.